

INSIDE TRACK CONFERENCE



Learning to care

3RD CONFERENCE ON ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER

12-13 February 2016
Milan, Italy

Chairs: C.H. Bangma, NL - J. Hugosson, SE

Co-Chair: L. Klotz, CAN

Honorary Chair: L.J. Denis, BE

Host Chair: R. Valdagni, IT

Scientific Coordinators: P. Carroll, US - M.J. Roobol, NL

In collaboration with



Endorsed by



FOREWORD

Over the years, there has been increasing acceptance of active surveillance as an important strategy for the treatment of low risk prostate cancer.

Unless the over-diagnosis of prostate cancer is reduced by alternative diagnostic strategies, active surveillance will continue to play an important role.

There is a rapid involvement in new imaging technologies and genomic biomarkers which may improve patient selection and monitoring. In addition there is the challenge if drugs and/or diet restrictions should be incorporated into active surveillance programmes.

ESO's third Conference on Active Surveillance for Low Risk Prostate Cancer organized in collaboration with EAU and endorsed by Europa Uomo aims at being an interactive educational activity in which attendees will enjoy presentations by internationally well recognized researchers on active surveillance, who have helped develop and evaluate technologies that may improve the selection and monitoring of low risk prostate cancer patients.

Workshops will allow all participants to discuss a few selected hot topics with the top experts in that field. The remarks and conclusions of the workshops will give important insights into how active surveillance practices are applied in various countries.

Finally, we would like to thank the European Association of Urology (EAU) and Europa Uomo for their support and also, on behalf of the Scientific Coordinators, the Co-Chair, the Honorary Chair and the organizing team, we invite you to participate and contribute to a productive and enjoyable conference.

Chris Bangma

Chair

Jonas Hugosson

Chair

Riccardo Valdagni

Host Chair

ESO Prostate Cancer

Programme Coordinator

FACULTY

- C. Bangma**, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
- L. Bellardita**, Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- L. Bokhorst**, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
- A. Briganti**, Urological Research Institute, Ospedale San Raffaele, Milan, IT
- S.M. Bruinsma**, Dept. of Public Health, Erasmus University Medical Center, Rotterdam, NL
- S. Carlsson**, Dept of Surgery and Dept of Urology, Memorial Sloan-Kettering Cancer Center, New York, US and Sahlgrenska Academy at the University of Gothenburg, SE
- P.R. Carroll**, Dept. of Urology, UCSF - Helen Diller Family, Comprehensive Cancer Center, University of California, San Francisco, US
- L.J. Denis**, Europa Uomo, Oncology Centre Antwerp, BE
- J. Humblet**, Europa Uomo, Mechelen, BE
- J. Hugosson**, Dept of Urology, Sahlgrenska Academy at the University of Gothenburg, SE
- G. Jenster**, Dept of Urology, Erasmus University Medical Center, Rotterdam, NL
- L.H. Klotz**, Division of Urology, Sunnybrook Health Sciences Centre, Toronto, CA
- I. Korfage**, Dept. of Public Health, Erasmus University Medical Center, University Medical Centre, Rotterdam, NL
- A. Lane**, School of Social and Community Medicine, University of Bristol, Bristol, UK
- C. Moore**, Dept. of Surgical and Interventional Science, University College, London, UK
- A. Ouzzane**, Service d'Urologie, Hopital Huriez, Centre Hospitalier Regional Universitaire, Lille, FR
- T. Pickles**, Dept. of Radiotherapy and Developmental Radiotherapeutics Radiation Oncology, BC Cancer Agency, Vancouver, CA
- A. Ranniko**, Dept of Urology, Helsinki University Hospital, Helsinki, FI
- M.J. Roobol**, Dept. of Urology/Epidemiology, Erasmus University Medical Center, Rotterdam, NL
- I. Schoots**, Dept. of Radiology, Erasmus University Medical Center, Rotterdam, NL
- A. Semjonow**, Dept. of Urology, University Hospital Munster, Munster, DE
- E. Steyerberg**, Dept. of Public Health, Erasmus University Medical Center, Rotterdam, NL
- K. Touijer**, Dept. of Surgery, Urology Service, Memorial Sloan-Kettering Cancer Center, New York, US
- B.J. Trock**, Department of Urology, Johns Hopkins School of Medicine, Baltimore, US
- R. Valdagni**, Prostate Cancer Programme and Division of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- H. Van Poppel**, Dept. Urology, University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, BE
- L. Venderbos**, Dept. of Urology, Erasmus University Medical Center, Rotterdam, NL
- J. Walz**, Dept. of Urology, Institut Paoli-Calmettes, Marseille, FR

FRIDAY, 12 FEBRUARY

9:00 **Welcome and introduction**

Welcome
Introduction

R. Valdagni, IT
C. Bangma, NL

9:15 **Overview of active surveillance in ERSPC**

J. Hugosson, SE

SESSION 1 - SETTING THE STAGE: DO WE NEED ACTIVE SURVEILLANCE IN THE FUTURE?

Chairs: J. Hugosson, SE - A. Semjonow, DE

9:30 Can we reduce over diagnosis?

M.J. Roobol, NL

9:50 Ethical and legal considerations

L. Venderbos, NL

10:10 An update on the Movember GAP-3 project

S.M. Bruinsma, NL

10:30 Discussion

10:40 *Coffee break*

SESSION 2 - CURRENT SELECTION OF MEN FOR ACTIVE SURVEILLANCE

Chairs: C. Bangma, NL - A. Briganti, IT

11:00 Traditional selection of men for active surveillance

K. Touijer, US

11:20 Broadening inclusion criteria (Gleason 3+4/ extended Gleason 3+3)

L. H. Klotz, CA

11:40 Risk-based selection for active surveillance

E. Steyerberg, NL

12:05 Value of MRI and targeted biopsies

P.R. Carroll, US

12:25 Better informed decision making to select more men for active surveillance

L.. Bellardita, IT

12:45 Structured panel discussion with input from audience

Panelists: L. Bellardita, IT - P.R. Carroll, US - L. Klotz, CA -
E. Steyerberg, NL - K. Touijer, US

13:15 *Lunch* and poster viewing

14:15 Presentation of the three best posters

EAU LECTURE

Chairs: H. Van Poppel, BE - B.J. Trock, US and Co-Chair to be announced

14:45 Imaging and active surveillance

J. Walz, FR

SESSION 3 - EVALUATION OF NEW PARAMETERS

Chairs: C. Moore, UK - B.J. Trock, US

15:15 Value of genetic profiles in active surveillance

S. Carlsson, US

15:30 Value of serum markers in active surveillance

B.J. Trock, US

15:45 The power of genetic profiling for low risk prostate cancer

G. Jenster, NL

16:00 Discussion

16:15 MRI to target biopsies

A. Ouzzane, FR

16:30 Objective parameters in MRI ?

I. Schoots, NL

16:45 Can MRI replace biopsies during follow-up?

C. Moore, UK

17:00 Discussion

17:30 **Sponsored lecture 1**

18:00 - **Sponsored lecture 2**

18:30

SATURDAY, 13 FEBRUARY

SESSION 4 - MONITORING OF MEN ON ACTIVE SURVEILLANCE

Chairs: T. Pickles, CA - R. Valdagni, IT

9:00	Number and frequency of follow-up tests	L. Bokhorst, NL
9:20	Triggers for reclassification	A. Rannikko, FI
9:40	When to stop active surveillance / switch to watchful waiting	A. Semjonow, DE
10:00	Active monitoring in the ProtecT study	A. Lane, UK
10:20	Highlights of the MRI Session	C. Moore, UK
10:30	Structured panel discussion with input from audience <i>Panelists:</i> L. Bokhorst, NL - A. Lane, UK - C. Moore, UK - A. Rannikko, FI - A. Semjonow, DE	

11:00 *Coffee break*

SESSION 5 - QUALITY OF LIFE OF MEN ON ACTIVE SURVEILLANCE

Chairs: L. Bellardita, IT and Co Chair to be announced

11:30	Can we better select men for active surveillance when adding psychological assessment?	A. Lane, UK
11:50	Comparison of long term quality of life between active surveillance and active treatment	I. Korfage, NL
12:10	Patient's perspective	J. Humblet, BE
12:30	Discussion	
12:45	<i>Lunch</i>	

SESSION 6 - SIMULTANEOUS WORKSHOPS (13:45 - 15:00)

Workshop #1 - *Which biomarkers/imaging/clinical characteristics should we use to select men with Gleason 3+4 for active surveillance?*
(M.J. Roobol, NL - S. Carlsson, US)

Workshop #2 - *Which quality of life measures should we routinely use in men on active surveillance? Which questions should still be answered?*
(L. Bellardita, IT - L. Venderbos, NL)

Workshop #3 - *What kind of interventions (food/ lifestyle/ medical) should we study in men on active surveillance? How to study them?*
(L.H. Klotz, CA - T. Pickles, CA)

Workshop #4 - *What should the definition of progression on MRI in men on active surveillance be? How to study it?*
(C. Moore, UK - I. Schoots, NL)

15:00 *Coffee break*

SESSION 7 - REPORTS OF THE WORKSHOPS (15:15 - 16:15)

Chairs: P.R. Carroll, US and Co-Chair to be announced

- **Workshop #1** (Speaker to be announced)
- **Workshop #2** (Speaker to be announced)
- **Workshop #3** (Speaker to be announced)
- **Workshop #4** (Speaker to be announced)

HOT DISCUSSION

Chairs: C. Bangma, NL and Co Chair to be announced

16:30	"Is selective identification of low risk prostate cancer currently possible or will it become possible in the near future?" <i>Panelists:</i> P.R. Carroll, CA - J. Hugosson, SE - L.H. Klotz, CA - M. J. Roobol, NL - K. Touijer, US - B.J. Trock, US - R. Valdagni, IT - H. Van Poppel, BE	
-------	---	--

17:00 - 17:10	Closing remarks	R. Valdagni, IT
------------------	-----------------	-----------------

ABSTRACT SUBMISSION

Deadline for submission: 9 December 2015

Submit online at www.eso.net

Participants are invited to submit abstract on research relating to the identification of potential indolent prostate cancer or on clinical studies relating to active surveillance of prostate cancer.

Abstracts will be considered for poster presentations only. The three best abstracts will be selected and presented both as posters and as a 10-minute oral presentation on Friday, 12 February 2016. The three best abstracts will furthermore be awarded a prize of € 200 each.

Ample opportunity will be given to the conference participants to view all posters. The Chair of the Poster Session will visit all posters and participants will be able to give a short oral explanation of the research described (no slides).

The Poster Session is scheduled on Friday, 12 February (13:15-14:15).

Accepted abstracts will be published in the event's dedicated website.

INSTRUCTIONS

- The number of words is limited: 50 words for the title (lower case letter) and 450 words (maximum 2800 characters) for the body of the abstract. The abstracts should be limited to 2000 characters, including the title.
- Tables and images are not accepted.
- Each author should be listed with First name, followed by Family Name.
- The first author will be the corresponding author and the presenter at the Conference.
- List the authors' affiliations. The same affiliation should be entered only once.
- The full address with e-mail address, phone and fax number of the first author (+corresponding author and presenter) must be provided. The first author will receive an acknowledgment of receipt and all subsequent communication by e-mail.
- For abstracts accepted for poster presentation and best abstract oral presentation, the first author will be the presenting author and is requested to register and participate in the Conference.
- It is responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of abstract will immediately follow the submission. The outcome will be notified by 15 December 2015 to the first author who will be required to register to the Conference (early registration deadline: 21 December 2015).

GENERAL INFORMATION

ORGANISING SECRETARIAT

European School of Oncology (ESO)
Via Turati 29 - 20121 Milan, Italy
www.eso.net

VENUE

Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian 1 - 20133 Milan, Italy
<http://www.istituto.tumori.mi.it>

Programme and organisation

Rita De Martini (prostata@eso.net) - Tel:+39 02 85464527 - Fax: +39 02 85464545

Registrations and abstracts:

Elena Fiore (efiore@eso.net) - Tel. + 39 02 85464529 - Fax: +39 02 85464545

ONLINE REGISTRATION

Registration may be carried out online at www.eso.net or by returning the enclosed registration form

REGISTRATION

The registration fee includes participation in all sessions, coffee breaks and lunches, and a copy of the Programme booklet. Registration will be confirmed by e-mail or by fax.

	Early (by 21 December 2015)	Late (by 31 January 2016)	On site (from 1 February 2016)
Registration fee	EUR 250	EUR 400	EUR 500
Club ESO Members	EUR 200		
EAU Members	EUR 200	EUR 100	EUR 100
Trainees*	EUR 100		

**(a supporting letter of Dept. Director is required)*

CANCELLATION OF REGISTRATION OR REPLACEMENT

Cancellations should be notified to ESO in writing by 30 January 2016. Replacement is allowed if written communication is received by 15 January 2016. In case of cancellation without replacement, the fee, less handling charges of EUR 100, will be refunded after the event.

CME ACCREDITATION

Participants will be entitled to receive a certificate of attendance at the close of the event by completing and submitting the on-line evaluation questionnaire.

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).

EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Information on the status of the applications can be obtained from the organising secretariat.

CREDITI CCC SIURO (*Società Italiana di Urologia Oncologica*)

Questo evento fa parte del percorso formativo SIURO

"Core Curriculum Uro-Onco-logico Certificate" e dà diritto a 12 crediti CCC.

Per maggiori informazioni consultare il sito www.siuro.it.



OFFICIAL LANGUAGE

The official language of the Conference is English: No simultaneous translation will be provided.

BADGE

The name badge is the only official evidence of registration and should be worn at all times during the Conference.

INSURANCE

The organisers bear no responsibility for untoward events in relation with the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.

REGISTRATION FORM

3RD ACTIVE SURVEILLANCE FOR LOW RISK PROSTATE CANCER, 12-13 FEBRUARY 2016, Milan, IT

Please fill in this form in **BLOCK LETTERS** and send by the deadline to:

European School of Oncology - Via Turati 29 - 20121 Milan - Italy - Fax: +39 02 85464545 - E mail: efiore@eso.net

ONLINE REGISTRATION IS AVAILABLE AT: WWW.ESO.NET

PARTICIPANT'S DETAILS

Dr. Prof. Mrs. Mr.

Surname Name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Date of birth Birth date (town and country)

Profession

Specialisation Main field

VAT number

Fiscal code (*Italian residents only*)

If your invoice details are different to those above, please complete the following section:

Invoice contact details

Address

Phone email

VAT number or Fiscal Code

**For organisation purposes, please select the workshop that you will attend
(see Workshop's title in the programme):**

Workshop N.1

Workshop N.2

Workshop N.3

Workshop N.4

REGISTRATION FEES:

Early
(by 21 December 2015)

Late
(by 31 January 2016)

On-site
(from 1 February 2016)

Registration fee EUR 250

EUR 400

EUR 500

Club ESO Members EUR 200

EUR 400

EUR 500

EAU Members EUR 200

EUR 400

EUR 500

Trainees* EUR 100

EUR 100

EUR 500

**(a supporting letter of Dept. Director is required)*

PAYMENT DETAILS:

The registration is processed when payment accompanies the form (credit card details or copy of bank transfer)

Visa/Mastercard Card Number / / /

Expire date / CV2 code

Holder's name (in CAPITAL LETTERS): and signature

BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer):

Bank: Banca Popolare di Milano, Agenzia 24 - Milan, Italy

Account holder: European School of Oncology

Number: No. 16333

IBAN: IT96G0558401624 0000000 16333 - **BIC:** BPMIITMMXXX

Reference: "3rd Active Surveillance Conference 2016" + your name

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date

